Recent advancements in the production, modification, and cellular delivery of RNA
molecules facilitated the expansion of RNA-based therapeutics. The increasing …

Cancer, infectious diseases, and metabolic and hereditary genetic disorders are a global
health burden affecting millions of people, with contemporary treatments offering limited …

Lipid nanoparticle (LNP)-based drug delivery systems have become the most clinically
advanced non-viral delivery technology. LNPs can encapsulate and deliver a wide variety of …

Ribonucleic acid (RNA) therapeutics are being actively researched as a therapeutic
modality in preclinical and clinical studies. They have become one of the most ubiquitously …

Nanotherapeutics demonstrate poor accumulation in the tumor microenvironment due to
poor extravasation and penetration into the tumor. Therapeutics such as oligonucleotides …

Abstract Treatment of patients with amyotrophic lateral sclerosis (ALS) has entered a new
era now that encouraging results about antisense oligonucleotides (ASOs) are becoming …

Recent years have seen unprecedented activity in the development of RNA-silencing
oligonucleotide therapeutics for metabolic diseases. Improved oligonucleotide design and …

The delivery of cures for retinal diseases remains problematic. There are four main
challenges: passing through multiple barriers of the eye, the delivery to particular retinal cell …

Acute activation of innate immune response in the brain, or neuroinflammation, protects this
vital organ from a range of external pathogens and promotes healing after traumatic brain …

Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …